The global medical community supports that vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for reaching the herd immunity threshold needed to curb the pandemic and return to normal life. Till now, a rapid development of coronavirus disease 2019 (COVID-19) vaccines has occurred and 7.45 billion doses have already administered worldwide. Although the efficacy and safety of COVID-19 vaccines have been tested in randomised clinical trials [1–3], some concerns have been raised based on very limited data regarding a non-immediate hypertensive response post vaccination.
